CLARITY News and Research

RSS

The lipid-exchanged, anatomically rigid, imaging/immunostaining compatible, tissue hydrogel (CLARITY) method was initially designed in 2013 by Chung and Deisseroth at the Stanford University School of Medicine. Using this process, post-mortem organs can be labeled for proteins and nucleic acids, enabling analysis of intact samples to create detailed 3D images.

Six Chicago high school students win CAP's 2010 'Path to a Future in Medicine' award

The College of American Pathologists (CAP) awarded six Chicago high school students the College's 2010 "Path to a Future in Medicine" award.

24 Sep 2010

CAP meeting to highlight medical diagnostic procedures

New science in cancer, genetic testing, molecular diagnostics, medical ethics, and gender-based disorders will be featured topics when nearly 1,200 pathologists gather at the Hyatt Regency Chicago on September 26 - 29 for the annual scientific meeting of the College of American Pathologists (CAP).

24 Sep 2010

Opinions: MDGs

"The overarching and noble goal [of this week's Millennium Development Goal (MDG) summit in New York] is reducing global poverty. But the most compelling and achievable objectives - huge reductions in maternal and child mortality worldwide - will be severely undermined if the Obama administration either directly or covertly integrates abortion into the final outcome document," Rep. Chris Smith (R-N.J.) writes in a Washington Post opinion piece.

21 Sep 2010

Financial Times analyzes increasing pressures on aid groups to demonstrate accomplishments with donor money

Ahead of the U.N. Millennium Development Summit, the Financial Times' Alan Beattie analyzes the effects of tightening aid budgets on development program funding, emphasizing how such changes are resulting in a push for increased measures to assess the effectiveness of aid.

18 Sep 2010

ISTA Pharmaceuticals initiates REMURA Phase 3 clinical program for dry eye disease

ISTA Pharmaceuticals, Inc., today announced that it has initiated a Phase 3 clinical program of ISTA's proprietary formulation of REMURA (bromfenac ophthalmic solution for dry eye) for alleviating the signs and symptoms of dry eye disease. The Phase 3 efficacy studies are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

16 Sep 2010

CRA appeals to FDA for name change allowance in high fructose corn syrup labeling

In an effort to help clarify the labeling of food products for consumers, the Corn Refiners Association (CRA) today petitioned the U.S. Food and Drug Administration (FDA) to allow manufacturers the option of using 'corn sugar' as an alternative name for high fructose corn syrup.

14 Sep 2010

Gates Foundation 2009 annual report released

The Bill & Melinda Gates Foundation on Tuesday released its 2009 annual report (.pdf) highlighting some of the foundation's work over the last year, the Puget Sound Business Journal reports (Holtzman, 9/7).

10 Sep 2010

Greater clarity on legal implications of testing incapacitated patients for blood-borne viruses needed

Anaesthetists are calling for greater clarity on the legal implications of testing incapacitated patients for blood-borne viruses, after a survey found that this is often done following staff needlestick injuries, in possible breach of UK legislation.

31 Aug 2010

Positron to host special ASNC 2010 symposium focusing on cardiac PET

Positron Corporation is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology annual meeting, September 23-26 in Philadelphia, PA.

30 Aug 2010

Trius commences oral torezolid phosphate Phase 3 clinical study for ABSSSI

Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.

30 Aug 2010

Authorities arrest more than 80 people, seize 10 tons of counterfeit meds in E. Africa

Authorities have arrested more than 80 people and seized 10 tons of counterfeit medicines across six East African countries, the international police agency Interpol announced Thursday, United Press International reports (8/26).

27 Aug 2010

Restat announces signing of PEBA as latest Align cost-plus pricing model client

Restat, the nation's largest independent pharmacy benefits manager has announced the signing of the Public Employee Benefits Alliance as its latest Align cost-plus pricing model client. PEBA, an organization formed by several Texas government employers, cooperatively purchases employee benefits -- including health care benefits -- on behalf of the local government entities.

26 Aug 2010

Inspire Pharmaceuticals, Allergan sign amended agreement for ophthalmic formulations

Inspire Pharmaceuticals, Inc. announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

25 Aug 2010

Urologix 2010 fourth quarter net loss decreases 28.9% to $0.04 per share

Urologix, a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for its fourth quarter ended June 30, 2010 and for fiscal year 2010.

25 Aug 2010

MWellA online community promotes awareness on mental disorders

Mental health is a hot button issue in today's society. People worry about the safety, cost, and multiple side-effects of anti-depressants and other psychoactive medications. Everyone wants to find peace of mind, contentment and happiness, but for many this struggle can prove overwhelming. Author and world organic food movement pioneer Paul Huljich addresses this issue in a Ning community he created for his organization MWellA (Mind Wellness Awareness)

24 Aug 2010

Scientists discover genetic flaw that causes facioscapulohumeral muscular dystrophy

Nearly two decades after they identified the specific genetic flaw that causes a common type of muscular dystrophy, scientists believe they have figured out how that flaw brings about the disease. The finding by an international team of researchers settles a longstanding question about the roots of facioscapulohumeral muscular dystrophy or FSHD.

20 Aug 2010

Daily dose of aspirin may reduce prostate cancer risk: US Study

A US study has found that a daily dose of aspirin may reduce the risk of prostate cancer, but Cancer Research UK has noted that regular use of aspirin can cause serious side-effects and should not be undertaken unless recommended by a doctor.Several previous studies have looked at the possibility of an association between aspirin use and a reduced risk of prostate cancer.In the latest study, scientists at the Fred Hutchinson Cancer Research Centre in Seattle, led by Dr Janet Stanford, looked at data on 1,001 prostate cancer patients and a similar number of cancer-free volunteers.

16 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Scientists develop new imaging technique to create three-dimensional images of melanoma

Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.

12 Aug 2010

Thomson Reuters earns Communication Seal from DALBAR for Personal Health Insights

Thomson Reuters has earned the Communication Seal from DALBAR, Inc. for its Personal Health Insights, an easy-to-read-and-understand health statement for individuals.

10 Aug 2010